New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors at an advisory committee meeting. | On second thought, the FDA figures it ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

For most investors, generating consistent income alongside capital appreciation is a common goal. For those seeking a blend ...

Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads ...

Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

A Canadian teen's breasts grew fourfold after receiving the Pfizer COVID-19 vaccine, raising concerns about a rare condition ...